NCT06848764

Brief Summary

This work aims to compare lidocaine and dexmedetomidine infusions for intraoperative bleeding in patients undergoing functional endoscopic sinus surgery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jul 2024

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2024

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2024

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

February 22, 2025

Completed
5 days until next milestone

First Posted

Study publicly available on registry

February 27, 2025

Completed
Last Updated

July 21, 2026

Status Verified

July 1, 2026

Enrollment Period

5 months

First QC Date

February 22, 2025

Last Update Submit

July 19, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Surgical field

    Surgical field will be assessed by Fromme et al. scale. (0-no bleeding, 1-slight bleeding, no suctioning of blood required, 2-slight bleeding occasional suctioning required, surgical field not threatened, 3-slight bleeding - frequent suctioning required. Bleeding threatens surgical field as few seconds after suction will be removed, 4-moderate bleeding - frequent suctioning required, bleeding threatens surgical field directly after suction will be removed, 5-severe bleeding - constant suctioning required, bleeding appeared faster than removed by suction. The surgical field severely threatened, and surgery not possible). The ideal category scale value will be determined to be ≤3.

    Intraoperatively

Secondary Outcomes (7)

  • Total morphine consumption

    24 hours postoperatively

  • Heart rate

    Till the end of surgery (Up to 4 hours)

  • Mean arterial pressure

    Till the end of surgery (Up to 4 hours)

  • Time to the first request for the rescue analgesia.

    24 hours postoperatively

  • Degree of pain

    24 hours postoperatively

  • +2 more secondary outcomes

Study Arms (2)

Lidocaine group

EXPERIMENTAL

Patients will receive lidocaine (1.5 mg/kg loading then 1mg/kg/h infusion) just after induction of anesthesia induction and continued until the end of the operation.

Drug: Lidocaine

Dexmedetomidine group

EXPERIMENTAL

Patients will receive 1 μg/kg dexmedetomidine infusion over 10 min as a loading dose then 0.4-0.7 μg/kg/h just after induction of anesthesia induction and continued until the end of the operation.

Drug: Dexmedetomidine

Interventions

Patients will receive lidocaine (1.5 mg/kg loading then 1mg/kg/h infusion) just after induction of anesthesia induction and continued until the end of the operation.

Lidocaine group

Patients will receive 1 μg/kg dexmedetomidine infusion over 10 min as a loading dose then 0.4-0.7 μg/kg/h just after induction of anesthesia induction and continued until the end of the operation.

Dexmedetomidine group

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age from 18 to 65 years old.
  • American Society of Anesthesiologists (ASA) physical status I - II.
  • Scheduled for elective functional endoscopic sinus surgery.

You may not qualify if:

  • Diabetes mellitus.
  • Coagulation disorders.
  • Kidney and liver dysfunction.
  • Cerebrovascular disease.
  • Cardiovascular problems.
  • High blood pressure.
  • Asthma.
  • Chronic obstructive pulmonary disease (COPD).
  • End organ damage.
  • Psychosis.
  • Taking antipsychotic drugs.
  • Allergy to study drugs.
  • Substance abuse.
  • Taking beta blockers.
  • Heart rate of \< 55 beat/minute.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ain Shams University

Cairo, 11591, Egypt

Location

MeSH Terms

Conditions

Blood Loss, Surgical

Interventions

LidocaineDexmedetomidine

Condition Hierarchy (Ancestors)

HemorrhagePathologic ProcessesPathological Conditions, Signs and SymptomsIntraoperative Complications

Intervention Hierarchy (Ancestors)

AcetanilidesAnilidesAmidesOrganic ChemicalsAniline CompoundsAminesImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Lecturer of Anesthesia, Intensive care, and pain management Faculty of Medicine Ain Shams University

Study Record Dates

First Submitted

February 22, 2025

First Posted

February 27, 2025

Study Start

July 1, 2024

Primary Completion

December 1, 2024

Study Completion

December 1, 2024

Last Updated

July 21, 2026

Record last verified: 2026-07

Data Sharing

IPD Sharing
Will share

The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

Shared Documents
STUDY PROTOCOL
Time Frame
After the end of study for one year.
Access Criteria
The data will be available upon a reasonable request from the corresponding author.

Locations